ライフサイエンスコーパス: impaired fasting glucose

1 terol, high triglycerides, hypertension, and impaired fasting glucose).

2 One subject taking placebo developed impaired fasting glucose.

3 d type 2 diabetes and 593 patients developed impaired fasting glucose.

4 th type 2 diabetes and 266 participants with impaired fasting glucose.

5 own hypertension, dyslipidemia, diabetes, or impaired fasting glucose.

6 ipoprotein cholesterol levels, and 15.3% had impaired fasting glucose.

7 among nondiabetic, postmenopausal women with impaired fasting glucose.

8 s and weaker among those without diabetes or impaired fasting glucose.

9 xperience the onset of diabetes mellitus and impaired fasting glucose.

10 ciated with higher incidence of diabetes and impaired fasting glucose.

11 also associated with increased prevalence of impaired fasting glucose.

12 e symptoms were 0.79 (95% CI, 0.63-0.99) for impaired fasting glucose, 0.75 (95% CI, 0.44-1.27) for u

13 rction had a higher annual incidence rate of impaired fasting glucose (1.8 vs 27.5% in our study) and

14 zed as normal fasting glucose (< 100 mg/dL), impaired fasting glucose (100-125 mg/dL), or type 2 diab

15 Impaired fasting glucose (100-125 vs. <90 mg/dL), elevat

16 having normal fasting glucose (<110 mg/dL), impaired fasting glucose (110 to <126 mg/dL), or undiagn

17 sterol (25.6%, 23.1-28.26%), and diabetes or impaired fasting glucose (25.0%, 22.6-27.5%).

18 ipants with normal fasting glucose; 27.9 for impaired fasting glucose; 31.2 for untreated type 2 diab

19 line), undiagnosed hyperglycemia (4.9%), and impaired fasting glucose (36.5% in those not known to be

20 te recovery was more common among those with impaired fasting glucose (42 vs. 31%; relative risk, 1.3

21 layers had significantly lower prevalence of impaired fasting glucose (6.7% [n = 24]; 95% CI, 4.6%-8.

22 Women with impaired fasting glucose according to either definition

23 The 218 women with impaired fasting glucose according to the 1997 definitio

24 CI, 1.08 to 1.74]), while the 698 women with impaired fasting glucose according to the 2003 definitio

25 196 (15%) had impaired glucose tolerance or impaired fasting glucose and 171 entered the trial.

26 re 27 diabetics and 50 prediabetics (17 with impaired fasting glucose and 33 with impaired glucose to

27 1.9-fold risk (95% CI, 1.5- to 2.4-fold) for impaired fasting glucose and a 3.7-fold risk (CI, 2.4- t

28 normal baseline fasting glucose, those with impaired fasting glucose and diabetes had adjusted relat

29 should be tested to evaluate the patient for impaired fasting glucose and diabetes mellitus.

30 e progression from normal fasting glucose to impaired fasting glucose and diabetes.

31 Impaired fasting glucose and IGT are associated with mod

32 al relationship between elevated lactate and impaired fasting glucose and insulin resistance.

33 10-139 mg/dL]) should be diagnosed as having impaired fasting glucose and treated with an appropriate

34 nd personal characteristics and incidence of impaired fasting glucose and type 2 diabetes.

35 tness was associated with increased risk for impaired fasting glucose and type 2 diabetes.

36 ted with the onset of objectively determined impaired fasting glucose and type 2 diabetes.

37 Impaired fasting glucose and untreated type 2 diabetes w

38 IGR was defined as impaired fasting glucose and/or impaired glucose toleran

39 idence of hyperglycemia (type 2 diabetes and impaired fasting glucose) and insulin regulation in a 9-

40 ia as a marker for diabetes and prediabetes (impaired fasting glucose) and insulin resistance in youn

41 A total of 504 participants (10%) had impaired fasting glucose, and 131 (3%) had untreated dia

42 eline, 734 women had diabetes, 218 women had impaired fasting glucose, and 1811 women were normoglyce

43 Incidences of diabetes, impaired fasting glucose, and cardiovascular events were

44 population and is associated with older age, impaired fasting glucose, and cirrhosis.

45 low HDL cholesterol, elevated triglycerides, impaired fasting glucose, and Dietary Guidelines for Ame

46 individuals, the prevalence of hypertension, impaired fasting glucose, and metabolic syndrome increas

47 latter included impaired glucose tolerance, impaired fasting glucose, and newly diagnosed diabetes).

48 betic patients and nondiabetic patients with impaired fasting glucose are at high risk of recurrent c

49 udy who were aged 42-60 y and free of T2D or impaired fasting glucose at baseline in 1984-1989.

50 Of the 7533 without impaired fasting glucose at baseline, 2514 (33%) develop

51 who were not diagnosed as diabetic, 342 had impaired fasting glucose at entry defined by the America

52 for developing diabetes: metabolic syndrome, impaired fasting glucose, body-mass index 30 kg/m(2) or

53 rease in the proportion of participants with impaired fasting glucose but not a clinical diagnosis of

54 concentration <6.1 mmol/L [110 mg/dL]); (2) impaired fasting glucose by the new criterion (FPG conce

55 intolerance (impaired glucose tolerance and impaired fasting glucose combined, 15.2%; previously und

56 omen, and with impaired glucose tolerance or impaired fasting glucose determined by oral glucose tole

57 rol and with increased odds of hypertension, impaired fasting glucose, diabetes mellitus, and metabol

58 Projections to 2020 suggest that obesity and impaired fasting glucose/diabetes mellitus could increas

59 ns such as metabolic syndrome, hypertension, impaired fasting glucose, family history of diabetes, ob

60 hout diagnosed diabetes; n = 55 (2.9%)), and impaired fasting glucose (fasting blood glucose 5.6-6.9

61 ation or fasting glucose > or =7 mmol/L) and impaired fasting glucose (fasting glucose > or =6.1 mmol

62 as no association between R3527Q variant and impaired fasting glucose, fasting glucose or insulin, or

63 abnormal metabolic features characterized by impaired fasting glucose, glucose intolerance, hyperinsu

64 ubjects with diabetes mellitus or those with impaired fasting glucose/glucose tolerance is therefore

65 These nondiabetic patients with impaired fasting glucose had a higher rate of recurrent

66 ard ratio per decade, 2.2; 95% CI, 1.7-2.7), impaired fasting glucose (hazard ratio, 2.6; 95% CI, 1.3

67 Among individuals with impaired fasting glucose, HbA1c concentrations were norm

68 current alcohol use, hypertension, diabetes/impaired fasting glucose, homeostatic model assessment o

69 1985 World Health Organization criteria) and impaired fasting glucose (IFG) (as defined by the 1997 A

70 pathway, was associated with development of impaired fasting glucose (IFG) after atenolol treatment.

71 Thirty-two subjects with impaired fasting glucose (IFG) and 28 subjects with norm

72 fects in beta-cell function in subjects with impaired fasting glucose (IFG) and compare the results t

73 Impaired fasting glucose (IFG) and impaired glucose tole

74 Impaired fasting glucose (IFG) and impaired glucose tole

75 ) for cardiovascular disease associated with impaired fasting glucose (IFG) and impaired glucose tole

76 dolescent weight gain and the development of impaired fasting glucose (IFG) and type 2 diabetes (T2DM

77 and clinical outcomes, in all patients with impaired fasting glucose (IFG) and type T2DM undergoing

78 ecretion and insulin action in subjects with impaired fasting glucose (IFG) and/or impaired glucose t

79 ied diabetes was found in 19% (n = 100), and impaired fasting glucose (IFG) and/or impaired glucose t

80 determine factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV-infected m

81 asis and their association with diabetes and impaired fasting glucose (IFG) in Fukuoka, Japanese subj

82 Impaired fasting glucose (IFG) is more prevalent in men

83 American Diabetes Association definition of impaired fasting glucose (IFG) on prevalence of IFG, cor

84 Pre-diabetes can be identified as either impaired fasting glucose (IFG) or impaired glucose toler

85 We sought to determine whether impaired fasting glucose (IFG) predicts cardiovascular d

86 A diagnosis of NODAT, IGT, and impaired fasting glucose (IFG) was based on World Health

87 he number of composite traits: hypertension, impaired fasting glucose (IFG), high fasting insulin, lo

88 ssion from normal glucose tolerance (NGT) to impaired fasting glucose (IFG), impaired glucose toleran

89 This study assessed whether impaired fasting glucose (IFG), insulin resistance, and

90 tion and treatment of asymptomatic diabetes, impaired fasting glucose (IFG), or impaired glucose tole

91 tion and beta-cell function in subjects with impaired fasting glucose (IFG).

92 ulin secretion and action and is preceded by impaired fasting glucose (IFG).

93 ey donors from 1994 to 2007 with predonation impaired fasting glucose (IFG).

94 udy was to assess the cardiovascular risk of impaired fasting glucose (IFG).

95 ic insulin resistance to the pathogenesis of impaired fasting glucose (IFG).

96 ation (FPG) as nondiabetic (FPG <110 mg/dl), impaired fasting glucose (IFG, FPG 110-125 mg/dl), and t

97 /dL (SD = 10.7), 18% of the participants had impaired fasting glucose (IFG; i.e., 100-125 mg/dL FBG)

98 vision incorporating the lower threshold for impaired fasting glucose [IFG]) and early-onset coronary

99 ic [T2D] case subjects, 192 individuals with impaired fasting glucose [IFG], and 1,897 control subjec

100 27 kg/m(2); 41 with type 2 diabetes, 15 with impaired fasting glucose [IFG], and 35 nondiabetic subje

101 eria, a new category was introduced, termed "impaired fasting glucose" (IFG).

102 curacies of 4 screening tests in identifying impaired fasting glucose, impaired glucose tolerance (IG

103 SPSTF reviewed the evidence on screening for impaired fasting glucose, impaired glucose tolerance, an

104 AGM was defined as impaired fasting glucose, impaired glucose tolerance, an

105 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or

106 high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or

107 thirds of patients (n = 28) met criteria for impaired fasting glucose/impaired glucose tolerance or d

108 in patients with type 2 diabetes mellitus or impaired fasting glucose/impaired glucose tolerance that

109 at in patients with type 2 diabetes mellitus/impaired fasting glucose/impaired glucose tolerance, a s

110 glucose tolerance: normal glucose tolerance, impaired fasting glucose/impaired glucose tolerance, or

111 isk factors for, development of diabetes and impaired fasting glucose in patients who have had a myoc

112 ndent risk factors for new-onset diabetes or impaired fasting glucose included older age, hypertensio

113 larger NFL players had a lower prevalence of impaired fasting glucose, less reported smoking, a simil

114 13.2%), dyslipidemia in 55 patients (25.1%), impaired fasting glucose level in 7 patients (3.2%), and

115 idemia (50%), elevated blood pressure (49%), impaired fasting glucose levels (26%), and diabetes mell

116 2.72]; P = .01) but were less likely to have impaired fasting glucose levels (adjusted relative risk

117 erval (C.I.) 1.39-3.92; P = 0.0015] and have impaired fasting glucose levels (odds ratio 3.53; 95% C.

118 risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was

119 Persons with impaired fasting glucose levels may also have increased

120 Of 23 patients with impaired fasting glucose levels of 111-126 mg/dl, 14 (61

121 high-sensitivity C-reactive protein levels, impaired fasting glucose levels, dyslipidemia, elevated

122 The risk of impaired fasting glucose levels, elevated blood pressure

123 In addition to diabetes and impaired fasting glucose levels, low fasting plasma gluc

124 ined associated with diabetes, hypertension, impaired fasting glucose, metabolic syndrome, HDL, trigl

125 in TG/HDL-C of 1.35 (CI, 1.26-1.45), and for impaired fasting glucose of 1.31 (CI, 1.05-1.64).

126 3859 (62%) of 6229 with the lower cutoff for impaired fasting glucose of 5.6 mmol/L (incidence 321 ca

127 at baseline, 2514 (33%) developed new-onset impaired fasting glucose or diabetes (incidence 123 case

128 fulfilled the inclusion criteria (NAFLD with impaired fasting glucose or impaired glucose tolerance)

129 with normal glucose tolerance and those with impaired fasting glucose or impaired glucose tolerance.

130 S. adults have diabetes and another 37% have impaired fasting glucose or impaired glucose tolerance.

131 This was not observed in patients with impaired fasting glucose or impaired glucose tolerance.

132 l glucose tolerance, and 21 participants had impaired fasting glucose or impaired glucose tolerance.

133 ), hypertension (OR 2.73, 95% CI 2.16-3.44), impaired fasting glucose (OR 2.95, 95% CI 2.32-3.75), in

134 cumference (OR, 1.30; 95% CI, 1.09 to 1.56), impaired fasting glucose (OR, 1.25; 95% CI, 1.05 to 1.48

135 6.76; for BMI >/=27.5 kg/m(2) ), diabetes or impaired fasting glucose (OR, 4.45; CI, 1.10-30.0), and

136 ary to diabetes, impaired glucose tolerance, impaired fasting glucose, or stress-induced is common in

137 VD risk factors (hypertension, dyslipidemia, impaired fasting glucose, or the metabolic syndrome).

138 (P<0.0001), hypertension (P<0.0001 to 0.01), impaired fasting glucose (P<0.0001 to 0.001), diabetes m

139 was influenced by the presence or absence of impaired fasting glucose (P=0.002 for the interaction) b

140 predictive of cardiovascular morbidity than impaired fasting glucose, probably because it is a bette

141 re affected and how undiagnosed diabetes and impaired fasting glucose relate to cognitive performance

142 y lipoprotein-cholesterol ratio TG/HDL-C, or impaired fasting glucose (serum glucose >/=110 mg/dL) to

143 about fasting blood glucose concentration or impaired fasting glucose status did not significantly im

144 Among participants with impaired fasting glucose, there were -8.3% (95% confiden

145 drug-naive patients with schizophrenia have impaired fasting glucose tolerance and are more insulin

146 This study examined the prevalence of impaired fasting glucose tolerance in first-episode, dru

147 irst-episode patients with schizophrenia had impaired fasting glucose tolerance, compared to none of

148 Impaired fasting glucose was associated with incident CV

149 Impaired fasting glucose was associated with increased i

150 The risk for impaired fasting glucose was elevated in older men and t

151 opathy (OR 3.01, 95% CI 1.60 to 5.65), while impaired fasting glucose was not (OR 1.55, 95% CI 0.70 t

152 nary artery disease, the 2003 definition for impaired fasting glucose was not associated with increas

153 nfidence interval [CI] = 1.29-2.83); whereas impaired fasting glucose was unassociated.

154 risk-factors with incidence of diabetes and impaired fasting glucose were assessed with multivariabl

155 etes and prediabetes (insulin resistance and impaired fasting glucose) were higher among persons with

156 3 nondiabetic men (of whom 7511 did not have impaired fasting glucose) who were examined at least twi